Moxonidine Tablet

MND-0.2

Moxonidine 0.2 mg Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Moxonidine IP — 0.2 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

MND-0.2 contains Moxonidine 0.2 mg, a centrally acting antihypertensive agent formulated for the effective management of essential hypertension and long-term cardiovascular protection. Moxonidine acts by selectively stimulating imidazoline I1 receptors in the brainstem, reducing sympathetic nervous system activity and lowering peripheral vascular resistance, resulting in effective blood pressure control with improved tolerability compared with many traditional centrally acting antihypertensive agents.

Moxonidine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, resistant hypertension, metabolic syndrome, obesity-associated hypertension, diabetes-associated hypertension, and increased sympathetic activity. It helps reduce systolic and diastolic blood pressure, improve insulin sensitivity, decrease sympathetic overactivity, and reduce cardiovascular risk.

MND-0.2 is particularly beneficial for patients initiating Moxonidine therapy, elderly hypertensive patients, individuals requiring moderate-dose antihypertensive treatment, metabolic syndrome, obesity, diabetes mellitus, chronic kidney disease, and patients requiring long-term antihypertensive therapy with favorable metabolic effects.

Technical Knowledge of Moxonidine

Moxonidine selectively stimulates central imidazoline I1 receptors located in the rostral ventrolateral medulla of the brainstem. Activation of these receptors suppresses sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, reduced renin secretion, and sustained blood pressure reduction.

Unlike older centrally acting agents, Moxonidine has greater selectivity for imidazoline receptors and less affinity for alpha-2 adrenergic receptors, contributing to a lower incidence of sedation, dry mouth, and other central nervous system adverse effects.

Mechanism of Action

Moxonidine stimulates central imidazoline I1 receptors, suppresses sympathetic nervous system activity, reduces peripheral vascular resistance, decreases heart rate, lowers blood pressure, reduces renin secretion, and improves autonomic cardiovascular regulation.

Key Benefits

Effective reduction of systolic and diastolic blood pressure

Reduces sympathetic overactivity

Provides sustained antihypertensive action

May improve insulin sensitivity

Supports cardiovascular protection

Favorable metabolic profile

Suitable for resistant hypertension

Convenient once-daily dosing

Suitable for long-term hypertension management under medical supervision

Clinical Applications

MND-0.2 is commonly prescribed for essential hypertension, resistant hypertension, hypertension with metabolic syndrome, hypertension with obesity, hypertension with diabetes mellitus, hypertension with chronic kidney disease, and long-term cardiovascular risk reduction.

Facts About Moxonidine

Moxonidine is a selective imidazoline receptor agonist with proven efficacy in reducing blood pressure through central sympathetic inhibition. It is particularly valuable in patients with metabolic syndrome, obesity, insulin resistance, and increased sympathetic activity. Clinical studies have demonstrated effective blood pressure reduction with favorable metabolic and autonomic effects. The 0.2 mg strength is commonly used for initiation and maintenance therapy in patients requiring individualized antihypertensive treatment.

Key Facts

Selective imidazoline I1 receptor agonist

Moxonidine 0.2 mg for sympathetic blood pressure control

Reduces central sympathetic activity

May improve insulin sensitivity

Favorable metabolic and cardiovascular profile

Evidence-based antihypertensive therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

MND-0.2 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, obesity, metabolic syndrome, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.

Why Choose MND-0.2 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Moxonidine 0.2 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

MND-0.2 from DIABGLYM combines effective blood pressure control, sympathetic modulation, favorable metabolic benefits, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Moxonidine formulation.